#BEGIN_DRUGCARD DB00374

# AHFS_Codes:
24:12.92

# ATC_Codes:
B01AC21

# Absorption:
Relatively rapid and complete after subcutaneous infusion, with an absolute bioavailability approximately 100%. In patients with mild (n=4) or moderate (n=5) hepatic insufficiency and portopulmonary hypertension following a subcutaneous dose of 10 ng per kg of body weight per min for 150 mins the AUC 0-&infin; was increased 3-fold and 5-fold respectively.

# Biotransformation:
Substantially metabolized by the liver, but the precise enzymes responsible are unknown. Five metabolites have been described (HU1 through HU5) however, the biological activity and metabolic fate of these are unknown. The chemical structure of HU1 is unknown. The metabolite HU5 is the glucuronide conjugate of treprostinil. The other metabolites are formed by oxidation of the 3-hydroxyoctyl side chain (HU2) and subsequent additional oxidation (HU3) or dehydration (HU4). Study results of in vitro human hepatic cytochrome P450 demonstrates that treprostinil does not inhibit CYP-1A2, 2C9, 2C19, 2D6, 2E1, or 3A. Whether treprostinil induces these enzymes has not been studied.

# Brand_Mixtures:
Not Available

# Brand_Names:
Remodulin
Viveta

# CAS_Registry_Number:
81846-19-7

# ChEBI_ID:
50861

# Chemical_Formula:
C23H34O5

# Chemical_IUPAC_Name:
2-{[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H,2H,3H,3aH,4H,9H,9aH-cyclopenta[b]naphthalen-5-yl]oxy}acetic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2246552

# Description:
Treprostinil is a synthetic analogue of prostacyclin, used to treat pulmonary hypertension. Treprostinil is marketed as Remodulin&reg;. [Wikipedia]

# Dosage_Forms:
Solution	Intravenous

# Drug_Category:
Antihypertensive Agents
Antithrombotic Agents
Vitamin K antagonists

# Drug_Interactions:
Abciximab	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Abciximab. Monitor for increased bleeding during concomitant thearpy.
Acebutolol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Acenocoumarol	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Acenocoumarol. Monitor for increased bleeding during concomitant thearpy.
Acetazolamide	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Acetylsalicylic acid	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Acetylsalicylic acid. Monitor for increased bleeding during concomitant thearpy.
Aliskiren	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Amiloride	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Aminosalicylic Acid	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the salicylate, Aminosalicylic acid. Monitor for increased bleeding during concomitant thearpy.
Amlodipine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Amyl Nitrite	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Anagrelide	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Anagrelide. Monitor for increased bleeding during concomitant thearpy.
Apraclonidine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Argatroban	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Argatroban. Monitor for increased bleeding during concomitant thearpy.
Atenolol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Benazepril	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Bendroflumethiazide	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Betaxolol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Bisoprolol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Bivalirudin	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Bivalirudin. Monitor for increased bleeding during concomitant thearpy.
Brimonidine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Bumetanide	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Candesartan	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Captopril	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Carteolol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Carvedilol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Celecoxib	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Celecoxib. Monitor for increased bleeding during concomitant thearpy.
Celiprolol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Chlorothiazide	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Chlorthalidone	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Cilazapril	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Cilostazol	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Cilostazol. Monitor for increased bleeding during concomitant thearpy.
Citalopram	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Citalopram. Monitor for increased bleeding during concomitant thearpy.
Clevidipine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Clonidine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Clopidogrel	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Clopidogrel. Monitor for increased bleeding during concomitant thearpy.
Cyclandelate	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Dexmedetomidine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Dichlorphenamide	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Diclofenac	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Diclofenac. Monitor for increased bleeding during concomitant thearpy.
Diflunisal	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Diflunisal. Monitor for increased bleeding during concomitant thearpy.
Diltiazem	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Dipyridamole	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Dipyridamole. Monitor for increased bleeding during concomitant thearpy. Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Doxazosin	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Drospirenone	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Drotrecogin alfa	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Drotrecogin alfa. Monitor for increased bleeding during concomitant thearpy.
Enalapril	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Enoxaparin	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Exoxaparin. Monitor for increased bleeding during concomitant thearpy.
Eplerenone	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Eprosartan	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Eptifibatide	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Eptifibatide. Monitor for increased bleeding during concomitant thearpy.
Escitalopram	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Escitalopram. Monitor for increased bleeding during concomitant thearpy.
Esmolol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Ethacrynic acid	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Etodolac	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Etodolac. Monitor for increased bleeding during concomitant thearpy.
Felodipine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Fenoprofen	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Fenoprofen. Monitor for increased bleeding during concomitant thearpy.
Fluoxetine	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Fluoxetine. Monitor for increased bleeding during concomitant thearpy.
Flurbiprofen	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Flurbiprofen. Monitor for increased bleeding during concomitant thearpy.
Fluvoxamine	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Fluvoxamine. Monitor for increased bleeding during concomitant thearpy.
Fosinopril	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Furosemide	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Guanabenz	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Guanfacine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Heparin	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Heparin. Monitor for increased bleeding during concomitant thearpy.
Hydralazine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Hydrochlorothiazide	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Hydroflumethiazide	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Ibuprofen	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ibuprofen. Monitor for increased bleeding during concomitant thearpy.
Indapamide	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Indomethacin	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Indomethacin. Monitor for increased bleeding during concomitant thearpy.
Irbesartan	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Isosorbide Dinitrate	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Isosorbide Mononitrate	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Isradipine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Ketoprofen	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ketoprofen. Monitor for increased bleeding during concomitant thearpy.
Ketorolac	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ketorolac. Monitor for increased bleeding during concomitant thearpy.
Labetalol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Lepirudin	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Lepirudin. Monitor for increased bleeding during concomitant thearpy.
Levobunolol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Lisinopril	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Losartan	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Lumiracoxib	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Lumiracoxib. Monitor for increased bleeding during concomitant thearpy.
Mannitol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Meclofenamic acid	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Meclofenamate. Monitor for increased bleeding during concomitant thearpy.
Mefenamic acid	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Mefenamic acid. Monitor for increased bleeding during concomitant thearpy.
Meloxicam	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Meloxicam. Monitor for increased bleeding during concomitant thearpy.
Methazolamide	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Methyclothiazide	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Metipranolol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Metolazone	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Metoprolol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Minoxidil	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Moexipril	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Nabumetone	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Nabumetone. Monitor for increased bleeding during concomitant thearpy.
Nadolol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Naproxen	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Naproxen. Monitor for increased bleeding during concomitant thearpy.
Nebivolol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Nesiritide	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Nicardipine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Nifedipine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Nimodipine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Nisoldipine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Nitrendipine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Nitroglycerin	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Nitroprusside	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Olmesartan	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Oxaprozin	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Oxaprozin. Monitor for increased bleeding during concomitant thearpy.
Oxprenolol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Papaverine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Paroxetine	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Paroxetine. Monitor for increased bleeding during concomitant thearpy.
Penbutolol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Perindopril	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Phenoxybenzamine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Phentolamine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Pindolol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Piroxicam	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Piroxicam. Monitor for increased bleeding during concomitant thearpy.
Polythiazide	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Prazosin	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Quinapril	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Ramipril	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Reserpine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Rivaroxaban	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Rivaroxaban. Monitor for increased bleeding during concomitant thearpy.
Salsalate	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the salicylate, Salsalate. Monitor for increased bleeding during concomitant thearpy.
Sertraline	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Sertraline. Monitor for increased bleeding during concomitant thearpy.
Sotalol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Spironolactone	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Sulindac	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Sulindac. Monitor for increased bleeding during concomitant thearpy.
Telmisartan	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Terazosin	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Tiaprofenic acid	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Tiaprofenic acid. Monitor for increased bleeding during concomitant thearpy.
Ticlopidine	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Ticlopidine. Monitor for increased bleeding during concomitant thearpy.
Timolol	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Tirofiban	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Tirofiban. Monitor for increased bleeding during concomitant thearpy.
Tizanidine	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Tolazoline	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Tolmetin	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Tolmetin. Monitor for increased bleeding during concomitant thearpy.
Torasemide	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Trandolapril	The prostacyclin analogue, Treprostinil, may increase the hypotensive effect of Trandolapril.
Triamterene	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Trichlormethiazide	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Urea	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Valsartan	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Verapamil	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Warfarin	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Warfarin. Monitor for increased bleeding during concomitant thearpy.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
4.1

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Insoluble at 25Â°C

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Treprostinil

# HET_ID:
Not Available

# Half_Life:
Terminal elimination half-life is approximately 2 to 4 hours. Plasma half-life is 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.

# InChI_Identifier:
InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1

# InChI_Key:
InChIKey=PAJMKGZZBBTTOY-ZFORQUDYSA-N

# Indication:
For use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
374

# Mechanism_Of_Action:
The major pharmacological actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In addition to treprostinil's direct vasodilatory effects, it also inhibits inflammatory cytokine. As a synthetic analogue of prostacyclin, it binds to the prostacyclin receptor, which subsequently induces the aforementioned downstream effects.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
390.5131

# Molecular_Weight_Mono:
390.240624198

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164768801

# Pharmacology:
Pulmonary arterial hypertension (PAH) is a disease in which blood pressure is abnormally high in the arteries between the heart and lungs. PAH is characterized by symptoms of shortness of breath during physical exertion. The condition can ultimately lead to heart failure. Treprostinil is a potent oral antiplatelet agent. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. Other studies have shown that treprostinil causes a dose-related negative inotropic and lusitropic effect. No major effects on cardiac conduction have been observed.

# Predicted_LogP_Hydrophobicity:
3.53

# Predicted_LogS:
-4.7

# Predicted_Water_Solubility:
7.31e-03 g/l

# Primary_Accession_No:
DB00374

# Protein_Binding:
Human plasma protein binding is approximately 91% in in vitro concentrations ranging from 330 to 10,000 &micro;/L.

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic/remodulin.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01272

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of treprostinil.

# Update_Date:
2013-02-08 16:19:17 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Treprostinil

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2C9

# Phase_1_Metabolizing_Enzyme_1_ID:
4757

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2C9

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P11712

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
15163595	Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, Seeger W: Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther. 2004 May;102(2):139-53.
18574748	Sprague RS, Bowles EA, Hanson MS, DuFaux EA, Sridharan M, Adderley S, Ellsworth ML, Stephenson AH: Prostacyclin analogs stimulate receptor-mediated cAMP synthesis and ATP release from rabbit and human erythrocytes. Microcirculation. 2008 Jul;15(5):461-71.
20622039	Falcetti E, Hall SM, Phillips PG, Patel J, Morrell NW, Haworth SG, Clapp LH: Smooth Muscle Proliferation and Role of the Prostacyclin (IP) Receptor in Idiopathic Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2010 Jul 9.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
PTGIR

# Drug_Target_1_GenBank_ID_Gene:
L29016

# Drug_Target_1_GenBank_ID_Protein:
495043

# Drug_Target_1_GeneCard_ID:
PTGIR

# Drug_Target_1_Gene_Name:
PTGIR

# Drug_Target_1_Gene_Sequence:
>1161 bp
ATGGCGGATTCGTGCAGGAACCTCACCTACGTGCGGGGCTCGGTGGGGCCGGCCACCAGC
ACCCTGATGTTCGTGGCCGGTGTGGTGGGCAACGGGCTGGCCCTGGGCATCCTGAGCGCA
CGGCGACCGGCGCGCCCCTCGGCCTTCGCGGTGCTGGTCACCGGACTGGCGGCCACCGAC
CTGCTGGGCACCAGCTTCCTGAGCCCGGCCGTGTTCGTGGCCTATGCGCGCAACAGCTCC
CTGCTGGGCCTGGCCCGAGGCGGCCCCGCCCTGTGCGATGCCTTCGCCTTCGCCATGACC
TTCTTCGGCCTGGCGTCCATGCTCATCCTCTTTGCCATGGCCGTGGAGCGCTGCCTGGCG
CTGAGCCACCCCTACCTCTACGCGCAGCTGGACGGGCCCCGCTGCGCCCGCCTGGCGCTG
CCAGCCATCTACGCCTTCTGCGTCCTCTTCTGCGCGCTGCCCCTGCTGGGCCTGGGCCAA
CACCAGCAGTACTGCCCCGGCAGCTGGTGCTTCCTCCGCATGCGCTGGGCCCAGCCGGGC
GGCGCCGCCTTCTCGCTGGCCTACGCCGGCCTGGTGGCCCTGCTGGTGGCTGCCATCTTC
CTCTGCAACGGCTCGGTCACCCTCAGCCTCTGCCGCATGTACCGCCAGCAGAAGCGCCAC
CAGGGCTCTCTGGGTCCACGGCCGCGCACCGGAGAGGACGAGGTGGACCACCTGATCCTG
CTGGCCCTCATGACAGTGGTCATGGCCGTGTGCTCCCTGCCTCTCACGATCCGCTGCTTC
ACCCAGGCTGTCGCCCCTGACAGCAGCAGTGAGATGGGGGACCTCCTTGCCTTCCGCTTC
TACGCCTTCAACCCCATCCTGGACCCCTGGGTCTTCATCCTTTTCCGCAAGGCTGTCTTC
CAGCGACTCAAGCTCTGGGTCTGCTGCCTGTGCCTCGGGCCTGCCCACGGAGACTCGCAG
ACACCCCTTTCCCAGCTCGCCTCCGGGAGGAGGGACCCAAGGGCCCCCTCTGCTCCTGTG
GGAAAGGAGGGGAGCTGCGTGCCTTTGTCGGCTTGGGGCGAGGGGCAGGTGGAGCCCTTG
CCTCCCACACAGCAGTCCAGCGGCAGCGCCGTGGGAACGTCGTCCAAAGCAGAAGCCAGC
GTCGCCTGCTCCCTCTGCTGA

# Drug_Target_1_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_1_General_References:
12488443	Miggin SM, Lawler OA, Kinsella BT: Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58. Epub 2002 Dec 17.
7512962	Boie Y, Rushmore TH, Darmon-Goodwin A, Grygorczyk R, Slipetz DM, Metters KM, Abramovitz M: Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem. 1994 Apr 22;269(16):12173-8.
7514139	Katsuyama M, Sugimoto Y, Namba T, Irie A, Negishi M, Narumiya S, Ichikawa A: Cloning and expression of a cDNA for the human prostacyclin receptor. FEBS Lett. 1994 May 9;344(1):74-8.
7665161	Ogawa Y, Tanaka I, Inoue M, Yoshitake Y, Isse N, Nakagawa O, Usui T, Itoh H, Yoshimasa T, Narumiya S, et al.: Structural organization and chromosomal assignment of the human prostacyclin receptor gene. Genomics. 1995 May 1;27(1):142-8.
7923647	Nakagawa O, Tanaka I, Usui T, Harada M, Sasaki Y, Itoh H, Yoshimasa T, Namba T, Narumiya S, Nakao K: Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation. 1994 Oct;90(4):1643-7.

# Drug_Target_1_HGNC_ID:
HGNC:9602

# Drug_Target_1_HPRD_ID:
08959

# Drug_Target_1_ID:
527

# Drug_Target_1_Locus:
19q13.3

# Drug_Target_1_Molecular_Weight:
40956

# Drug_Target_1_Name:
Prostacyclin receptor

# Drug_Target_1_Number_of_Residues:
386

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Celecoxib Pathway	SMP00096
Etodolac Pathway	SMP00084
Meloxicam Pathway	SMP00106
Rofecoxib Pathway	SMP00087
Valdecoxib Pathway	SMP00116

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Prostacyclin receptor
MADSCRNLTYVRGSVGPATSTLMFVAGVVGNGLALGILSARRPARPSAFAVLVTGLAATD
LLGTSFLSPAVFVAYARNSSLLGLARGGPALCDAFAFAMTFFGLASMLILFAMAVERCLA
LSHPYLYAQLDGPRCARLALPAIYAFCVLFCALPLLGLGQHQQYCPGSWCFLRMRWAQPG
GAAFSLAYAGLVALLVAAIFLCNGSVTLSLCRMYRQQKRHQGSLGPRPRTGEDEVDHLIL
LALMTVVMAVCSLPLTIRCFTQAVAPDSSSEMGDLLAFRFYAFNPILDPWVFILFRKAVF
QRLKLWVCCLCLGPAHGDSQTPLSQLASGRRDPRAPSAPVGKEGSCVPLSAWGEGQVEPL
PPTQQSSGSAVGTSSKAEASVACSLC

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase

# Drug_Target_1_SwissProt_ID:
P43119

# Drug_Target_1_SwissProt_Name:
PI2R_HUMAN

# Drug_Target_1_Synonyms:
PGI receptor
Prostaglandin I2 receptor
Prostanoid IP receptor

# Drug_Target_1_Theoretical_pI:
8.53

# Drug_Target_1_Transmembrane_Regions:
17-38
52-76
95-115
135-158
182-208
236-260
275-295

# Drug_Target_2_Cellular_Location:
Nucleus

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
16239641	Ali FY, Egan K, FitzGerald GA, Desvergne B, Wahli W, Bishop-Bailey D, Warner TD, Mitchell JA: Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol. 2006 Feb;34(2):242-6. Epub 2005 Oct 20.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
PPARD

# Drug_Target_2_GenBank_ID_Gene:
L07592

# Drug_Target_2_GenBank_ID_Protein:
190230

# Drug_Target_2_GeneCard_ID:
PPARD

# Drug_Target_2_Gene_Name:
PPARD

# Drug_Target_2_Gene_Sequence:
>1326 bp
ATGGAGCAGCCACAGGAGGAAGCCCCTGAGGTCCGGGAAGAGGAGGAGAAAGAGGAAGTG
GCAGAGGCAGAAGGAGCCCCAGAGCTCAATGGGGGACCACAGCATGCACTTCCTTCCAGC
AGCTACACAGACCTCTCCCGGAGCTCCTCGCCACCCTCACTGCTGGACCAACTGCAGATG
GGCTGTGACGGGGCCTCATGCGGCAGCCTCAACATGGAGTGCCGGGTGTGCGGGGACAAG
GCATCGGGCTTCCACTACGGTGTTCATGCATGTGAGGGGTGCAAGGGCTTCTTCCGTCGT
ACGATCCGCATGAAGCTGGAGTACGAGAAGTGTGAGCGCAGCTGCAAGATTCAGAAGAAG
AACCGCAACAAGTGCCAGTACTGCCGCTTCCAGAAGTGCCTGGCACTGGGCATGTCACAC
AACGCTATCCGTTTTGGTCGGATGCCGGAGGCTGAGAAGAGGAAGCTGGTGGCAGGGCTG
ACTGCAAACGAGGGGAGCCAGTACAACCCACAGGTGGCCGACCTGAAGGCCTTCTCCAAG
CACATCTACAATGCCTACCTGAAAAACTTCAACATGACCAAAAAGAAGGCCCGCAGCATC
CTCACCGGCAAAGCCAGCCACACGGCGCCCTTTGTGATCCACGACATCGAGACATTGTGG
CAGGCAGAGAAGGGGCTGGTGTGGAAGCAGTTGGTGAATGGCCTGCCTCCCTACAAGGAG
ATCAGCGTGCACGTCTTCTACCGCTGCCAGTGCACCACAGTGGAGACCGTGCGGGAGCTC
ACTGAGTTCGCCAAGAGCATCCCCAGCTTCAGCAGCCTCTTCCTCAACGACCAGGTTACC
CTTCTCAAGTATGGCGTGCACGAGGCCATCTTCGCCATGCTGGCCTCTATCGTCAACAAG
GACGGGCTGCTGGTAGCCAACGGCAGTGGCTTTGTCACCCGTGAGTTCCTGCGCAGCCTC
CGCAAACCCTTCAGTGATATCATTGAGCCTAAGTTTGAATTTGCTGTCAAGTTCAACGCC
CTGGAACTTGATGACAGTGACCTGGCCCTATTCATTGCGGCCATCATTCTGTGTGGAGAC
CGGCCAGGCCTCATGAACGTTCCACGGGTGGAGGCTATCCAGGACACCATCCTGCGTGCC
CTCGAATTCCACCTGCAGGCCAACCACCCTGATGCCCAGTACCTCTTCCCCAAGCTGCTG
CAGAAGATGGCTGACCTGCGGCAACTGGTCACCGAGCACGCCCAGATGATGCAGCGGATC
AAGAAGACCGAAACCGAGACCTCGCTGCACCCTCTGCTCCAGGAGATCTACAAGGACATG
TACTAA

# Drug_Target_2_General_Function:
Involved in DNA binding

# Drug_Target_2_General_References:
10851270	Skogsberg J, Kannisto K, Roshani L, Gagne E, Hamsten A, Larsson C, Ehrenborg E: Characterization of the human peroxisome proliferator activated receptor delta gene and its expression. Int J Mol Med. 2000 Jul;6(1):73-81.
1333051	Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA: Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol. 1992 Oct;6(10):1634-41.
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.

# Drug_Target_2_HGNC_ID:
HGNC:9235

# Drug_Target_2_HPRD_ID:
02679

# Drug_Target_2_ID:
1502

# Drug_Target_2_Locus:
6p21.2-p21.1

# Drug_Target_2_Molecular_Weight:
49904

# Drug_Target_2_Name:
Peroxisome proliferator-activated receptor delta

# Drug_Target_2_Number_of_Residues:
441

# Drug_Target_2_PDB_ID:
1Y0S

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00104	Hormone_recep
PF00105	zf-C4

# Drug_Target_2_Protein_Sequence:
>Peroxisome proliferator-activated receptor delta
MEQPQEEAPEVREEEEKEEVAEAEGAPELNGGPQHALPSSSYTDLSRSSSPPSLLDQLQM
GCDGASCGSLNMECRVCGDKASGFHYGVHACEGCKGFFRRTIRMKLEYEKCERSCKIQKK
NRNKCQYCRFQKCLALGMSHNAIRFGRMPEAEKRKLVAGLTANEGSQYNPQVADLKAFSK
HIYNAYLKNFNMTKKKARSILTGKASHTAPFVIHDIETLWQAEKGLVWKQLVNGLPPYKE
ISVHVFYRCQCTTVETVRELTEFAKSIPSFSSLFLNDQVTLLKYGVHEAIFAMLASIVNK
DGLLVANGSGFVTREFLRSLRKPFSDIIEPKFEFAVKFNALELDDSDLALFIAAIILCGD
RPGLMNVPRVEAIQDTILRALEFHLQANHPDAQYLFPKLLQKMADLRQLVTEHAQMMQRI
KKTETETSLHPLLQEIYKDMY

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Decreases expression of NPC1L1 once activated by a ligand

# Drug_Target_2_SwissProt_ID:
Q03181

# Drug_Target_2_SwissProt_Name:
PPARD_HUMAN

# Drug_Target_2_Synonyms:
NUC1
NUCI
Nuclear hormone receptor 1
PPAR- beta
PPAR-delta

# Drug_Target_2_Theoretical_pI:
7.65

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
P2RY12

# Drug_Target_3_GenBank_ID_Gene:
AF313449

# Drug_Target_3_GenBank_ID_Protein:
12083902

# Drug_Target_3_GeneCard_ID:
P2RY12

# Drug_Target_3_Gene_Name:
P2RY12

# Drug_Target_3_Gene_Sequence:
>1029 bp
ATGCAAGCCGTCGACAACCTCACCTCTGCGCCTGGGAACACCAGTCTGTGCACCAGAGAC
TACAAAATCACCCAGGTCCTCTTCCCACTGCTCTACACTGTCCTGTTTTTTGTTGGACTT
ATCACAAATGGCCTGGCGATGAGGATTTTCTTTCAAATCCGGAGTAAATCAAACTTTATT
ATTTTTCTTAAGAACACAGTCATTTCTGATCTTCTCATGATTCTGACTTTTCCATTCAAA
ATTCTTAGTGATGCCAAACTGGGAACAGGACCACTGAGAACTTTTGTGTGTCAAGTTACC
TCCGTCATATTTTATTTCACAATGTATATCAGTATTTCATTCCTGGGACTGATAACTATC
GATCGCTACCAGAAGACCACCAGGCCATTTAAAACATCCAACCCCAAAAATCTCTTGGGG
GCTAAGATTCTCTCTGTTGTCATCTGGGCATTCATGTTCTTACTCTCTTTGCCTAACATG
ATTCTGACCAACAGGCAGCCGAGAGACAAGAATGTGAAGAAATGCTCTTTCCTTAAATCA
GAGTTCGGTCTAGTCTGGCATGAAATAGTAAATTACATCTGTCAAGTCATTTTCTGGATT
AATTTCTTAATTGTTATTGTATGTTATACACTCATTACAAAAGAACTGTACCGGTCATAC
GTAAGAACGAGGGGTGTAGGTAAAGTCCCCAGGAAAAAGGTGAACGTCAAAGTTTTCATT
ATCATTGCTGTATTCTTTATTTGTTTTGTTCCTTTCCATTTTGCCCGAATTCCTTACACC
CTGAGCCAAACCCGGGATGTCTTTGACTGCACTGCTGAAAATACTCTGTTCTATGTGAAA
GAGAGCACTCTGTGGTTAACTTCCTTAAATGCATGCCTGGATCCGTTCATCTATTTTTTC
CTTTGCAAGTCCTTCAGAAATTCCTTGATAAGTATGCTGAAGTGCCCCAATTCTGCAACA
TCTCTGTCCCAGGACAATAGGAAAAAAGAACAGGATGGTGGTGACCCAAATGAAGAGACT
CCAATGTAA

# Drug_Target_3_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_3_General_References:
11104774	Zhang FL, Luo L, Gustafson E, Lachowicz J, Smith M, Qiao X, Liu YH, Chen G, Pramanik B, Laz TM, Palmer K, Bayne M, Monsma FJ Jr: ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J Biol Chem. 2001 Mar 16;276(11):8608-15. Epub 2000 Dec 4.
11196645	Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001 Jan 11;409(6817):202-7.
11502873	Takasaki J, Kamohara M, Saito T, Matsumoto M, Matsumoto S, Ohishi T, Soga T, Matsushime H, Furuichi K: Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol. 2001 Sep;60(3):432-9.
12044878	Takeda S, Kadowaki S, Haga T, Takaesu H, Mitaku S: Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett. 2002 Jun 5;520(1-3):97-101.

# Drug_Target_3_HGNC_ID:
HGNC:18124

# Drug_Target_3_HPRD_ID:
02743

# Drug_Target_3_ID:
122

# Drug_Target_3_Locus:
3q24-q25

# Drug_Target_3_Molecular_Weight:
39439

# Drug_Target_3_Name:
P2Y purinoceptor 12

# Drug_Target_3_Number_of_Residues:
342

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Abciximab Pathway	SMP00265
Acetylsalicylic Acid Pathway	SMP00083
Celecoxib Pathway	SMP00096
Cilostazol Pathway	SMP00263
Clopidogrel Pathway	SMP00260
Dipyridamole (Antiplatelet) Pathway	SMP00264
Eptifibatide Pathway	SMP00266
Etodolac Pathway	SMP00084
Meloxicam Pathway	SMP00106
Rofecoxib Pathway	SMP00087
Ticlopidine Pathway	SMP00261
Tirofiban Pathway	SMP00267
Valdecoxib Pathway	SMP00116

# Drug_Target_3_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_3_Protein_Sequence:
>P2Y purinoceptor 12
MQAVDNLTSAPGNTSLCTRDYKITQVLFPLLYTVLFFVGLITNGLAMRIFFQIRSKSNFI
IFLKNTVISDLLMILTFPFKILSDAKLGTGPLRTFVCQVTSVIFYFTMYISISFLGLITI
DRYQKTTRPFKTSNPKNLLGAKILSVVIWAFMFLLSLPNMILTNRQPRDKNVKKCSFLKS
EFGLVWHEIVNYICQVIFWINFLIVIVCYTLITKELYRSYVRTRGVGKVPRKKVNVKVFI
IIAVFFICFVPFHFARIPYTLSQTRDVFDCTAENTLFYVKESTLWLTSLNACLDPFIYFF
LCKSFRNSLISMLKCPNSATSLSQDNRKKEQDGGDPNEETPM

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Involved in platelets aggregation

# Drug_Target_3_SwissProt_ID:
Q9H244

# Drug_Target_3_SwissProt_Name:
P2Y12_HUMAN

# Drug_Target_3_Synonyms:
ADP-glucose receptor
ADPG-R
P2T(AC)
P2Y(AC)
P2Y(ADP)
P2Y(cyc)
P2Y12
P2Y12 platelet ADP receptor
SP1999

# Drug_Target_3_Theoretical_pI:
9.99

# Drug_Target_3_Transmembrane_Regions:
26-46
59-79
100-120
143-163
192-212
234-254
282-302

#END_DRUGCARD DB00374
